Disclosure Statement Pursuant to the OTCID Disclosure Guidelines

LiveWire Ergogenics, Inc.

A Nevada Corporation

5165 Estrella Road
Paso Robles, CA 93446

714-740-5144
info@livewireergogenics.com
SIC Code: 2060

Quarterly Report

For the Period Ending: June 30, 2026
(the "Reporting Period")

As of June 31, 2026, the number of shares outstanding of our Common Stock was 1,903,979,092
As of December 31, 2025, the number of shares outstanding of our Common Stock was 1,903,979,092
As of December 31, 2024, the number of shares outstanding of our Common Stock was 1,903,979,092

Shell Status

Indicate by check mark whether the Company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the Company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

Change in Control

Indicate by check mark whether a Change in Control of the Company has occurred over this reporting period:

Yes: ☐ No: ☒

1) Name and address(es) of the issuer and its predecessors (if any)

Semper Flowers, Inc. 10/9/2007 to 5/15/2009
SF Blu Vu, Inc. 5/15/2009 to 9/20/2011

Livewire Ergogenics, Inc. 9/20/2011 to 12/31/2024
1600 N Kraemer Blvd,
Anaheim CA 92806

Livewire Ergogenics, Inc., 1/1/2025 to present
5165 Estrella Road
Paso Robles, CA 93446

Incorporated in Nevada on October 9, 2007, Status: Active

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

NONE

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

NONE

The address(es) of the issuer's principal executive office:

Livewire Ergogenics, Inc.
5165 Estrella Road
Paso Robles, CA 93446

The address(es) of the issuer's principal place of business:
Check box if the principal executive office and principal place of business are the same address: ☒

Has the issuer or its predecessors been in bankruptcy, receivership, or a similar proceeding in the past five years?

Yes: ☐ No: ☒

2) Security Information

Transfer Agent

Name:	Continental Stock Transfer & Trust
Phone:	212-856-32183
Email:	eyoung@continentalstock.com
Address:	1 State Street, 30th Floor New York NY 10004-1561

Is the Transfer Agent registered under the Exchange Act? Yes: ☒ No: ☐

Publicly Quoted or Traded Securities:

Trading symbol:	LVVV	
Exact title and class of securities outstanding:	Common	
CUSIP:	53838A 104	
Par or stated value:	$0.0001	
Total shares authorized:	2,000,000,000	as of date: 6.30/2026
Total shares outstanding:	1,903,979,092	as of date: 6.30/2026
Number of shares in the Public Float:	961,943,202	as of date: 6.30/2026
Total number of shareholders of record:	6,651+	as of date: 6.30/2026

All additional classes (es) of publicly traded securities (if any): NONE

Other classes of authorized or outstanding equity securities:

Trading symbol:	n/a
Exact title and class of securities outstanding:	Class B Preferred
CUSIP:	n/a

Par or stated value:	$0.0001	
Total shares authorized:	100,000	as of date: 6.30/2026
Total shares outstanding:	32,820	as of date: 6.30/2026

Trading symbol:	n/a	
Exact title and class of securities outstanding:		Class C Preferred
CUSIP:	n/a	
Par or stated value:	$0.0001	
Total shares authorized:	75	as of date: 6.30/2026
Total shares outstanding:	75	as of date: 6.30/2026

<u>Security Description:</u>

1. For common equity, describe any dividend, voting, and preemption rights.

   Each share of Common Stock is entitled to convert into one (1) share of regular common stock at any time at the holder's option and to cast two hundred (200) votes on all matters as to which holders of the common stock, voting together as a class, are entitled to vote; the shares have no preemptive rights and no dividend payment.

2. For preferred stock, describe the dividend, voting, conversion, liquidation rights, and redemption or sinking fund provisions.

   Each outstanding share of Series B Preferred Stock shall vote with the common stock on all matters. The shares of Series B Preferred Stock shall (i) have a liquidation preference of $1.00 per share; (ii) accrue, earn, or participate in any dividends on the common stock; and (iii) be subject to redemption by the Corporation.

   Each share of Series C Preferred has the right to convert into 8,000 shares of the Company’s common stock and has a liquidation preference of $200. Additionally, the Series C Preferred is allowed to vote on all matters that the Company's shareholders are permitted to vote on, equal to .7% of all outstanding securities eligible to vote at the time of such shareholder action for each share of Series C Preferred.

3. Describe any other material rights of common or preferred stockholders.

   NONE

4. Describe any material modifications to the rights of the holders of the company’s securities that have occurred over the reporting period covered by this report.

   NONE

3) Issuance History

A. Changes to the Number of Outstanding Shares

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years.:

No: X Yes: (If yes, you must complete the table below

Number of Shares outstanding as of December 31, 2020	Opening Balance: Common: 1,232,544,557 Preferred: 32,895								
Date of Transaction	**Transaction type (e.g., issuance, cancellation, shares returned to treasury)**	**Number of Shares Issued (or canceled)**	**Class of Securities**	**Value of shares issued ($/per share) at Issuance**	**Were the shares issued at a discount to the market price at the time**	**Individual/ Entity Shares were issued to (entities must have individuals with voting/investment control disclosed).**	**Reason for share issuance (e.g., for cash or debt conversion) OR Nature of Services Provided (if applicable)**	**Restricted or Unrestricted as of this filing**	**Exemption or Registration Type?**
Shares Outstanding on 3/31/2026	Ending Balance: Common: 1,903,979,092 Preferred: 37,895								

Additional details, including footnotes to the table above: NONE

B. Outstanding promissory, convertible notes, or debt arrangements:

Indicate by check mark whether there are any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities:

No: ☐ Yes: **X** (If yes, you must complete the table below)

Date of Note Issuance	Outstanding Balance ($)	Principal Amount at Issuance ($)	Interest Accrued ($)	Maturity Date	Conversion Terms (e.g., pricing mechanism for the conversion of instrument to shares)	Name of Noteholder	Reason for Issuance (e.g., Loan, Services, etc.)
8/1/12	$10,927	$10,000	$7,346	12/31/22	None	United Capital/Chris MacDougall	Loan
4/16/18	$163,909	$100,000	$63,909	12/16/18	None	JC Loans/Wm. Riley	Loan
7/26/18	$80,883	$65,000	$13,495	12/31/22	None	Larry Whitehead	Loan
03/01/19	$591,727	$500,000	$91,727	06/01/19	None	Tom Cling	Loan
7/17/19	$5,464	$5,000	$2,964	7/17/2020	None	JE Prince	Loan
5/15/22	$1,074,312	$948,689	$126,622	5/15/24	None	Peachtree/I Gains	Cons Loan
8/10/22	$109.273	$100,000	$14,273	8/10/23	None	Peachtree/I Gains	Loan
4/1/20	$163,909	$160,000	$17,659	4/1/2024	None	Rainer Poertner	Cons Loan

05/26/20	$280,000	$300,000	0	6/1/2023	None	Donovan Anderson	Loan
5/8/2022	$382.923	$250,000	$42,494	5/8/2023	None	Osher Investments/ Meghan Konecne	Loan
7/12/2022	$54,636	$50,000	$9.636	12/12/22	None	Joe Caponetta	Loan
4/24/2023	$54,636	$50,000	$5.436	11/30/23	None	Jared Mercer	Loan
6/6/2023	$54,636	$50,000	$5,052	1/6/23	None	Donal Barry	Loan
6/16/2023	$92,888	$92,888	0	6/16/2024	None	J.Dole Group / Jeff Dole	Loan

Additional details, including footnotes to the table above: NONE

4) Issuer's Business, Products, and Services

Business Operations

LiveWire Ergogenics, Inc. ("LiveWire" or the "Company"), together with its affiliates and strategic partners, develops, licenses, markets, and distributes distinctive, high-quality cannabinoid, hemp-derived THC, CBD, and general wellness products and accessories. The Company's portfolio includes its proprietary SOL VIDA™ Wellness brand and other cannabinoid-based and functional wellness products,

Depending on product formulation and applicable law, the Company's products are intended for business-to-business and direct-to-consumer distribution through appropriately licensed distributors, dispensary chains, delivery services, retail outlets, and online sales channels in California and other permitted U.S. markets. Product availability and distribution are subject to manufacturing schedules, federal, state, and local laws governing each product and jurisdiction.

LiveWire and its affiliates are committed to using high-quality, distinctive ingredients in the development of the Company's specialty wellness products. LiveWire does not knowingly manufacture, market, sell, or distribute any product in violation of the United States Controlled Substances Act or other applicable federal, state, or local laws.

Transition from Cultivation to Functional Wellness

During the first quarter of 2025, Estrella Ranch Partners, LLC ("ERP") ceased cultivation operations and ownership of Estrella Ranch as part of LiveWire's strategic transition away from capital-intensive cannabis cultivation and unpredictable bulk flower sales. This decision was made to eliminate the substantial operating costs and administrative, regulatory, and financial burdens associated with maintaining large-scale cultivation operations.

ERP subsequently transferred the Grant Deed for Estrella Ranch back to the original owners, terminating Estrella Ranch Partner's (ERP's) and LiveWire's continuing administrative and financial obligations associated with ownership of the property. These transactions have been completed.

LiveWire has since streamlined its operations and redirected its resources toward cannabinoid-based and custom-designed functional wellness products. The transition delayed near-term revenue recognition, with limited revenue recognized during the first and second quarters of 2026 and modest increases expected during the third quarter of 2026.

Management believes this strategy will substantially reduce the operational obstacles, regulatory limitations, and tax burdens associated with the traditional cannabis market. It will also position the Company to address the considerably larger general wellness market with products designed to generate higher profit margins and more stable, predictable, year-round revenue.

Development of the Company's new product portfolio is underway. LiveWire expects to introduce additional cannabinoid and functional wellness products during 2026, supported by targeted online marketing and product-awareness campaigns.

Product Development and Strategic Partnerships

The Company has established relationships with carefully selected wellness-product developers and producers to support the SOL VIDA™ Wellness product line. LiveWire is also working with experienced cannabis professionals, manufacturers, processors, and other qualified industry participants to expand its cannabinoid product portfolio.

Certain LiveWire affiliates' remaining inventory is being processed and converted into high-quality cannabinoid oil intended for use in the Company's new hemp-derived THC, CBD, cannabinoid, and functional wellness products. The Company's affiliate, Estrella River Farms ("ERF"), has delivered its remaining bulk raw materials into inventory, making those materials available for further processing and conversion into finished products, subject to applicable legal and regulatory requirements.

LiveWire plans to begin marketing and selling its new product line during the third quarter of 2026, with commercial activity expected to accelerate during the third and fourth quarters. The timing and extent of product introductions and revenue generation will depend on manufacturing readiness, regulatory compliance, distribution arrangements, market acceptance, and other commercial factors.

Compliance and Expansion Strategy

LiveWire intends to conduct business only with companies, affiliates, and strategic partners that comply with all applicable federal, state, and local laws and regulations and maintain the licenses, permits, and approvals required for their respective operations.

The Company intends to expand its product-development, manufacturing, supply, and distribution networks to support a broader portfolio of distinctive, high-quality, competitively priced wellness products. LiveWire also plans to strengthen its brands through focused and aggressive marketing campaigns while maintaining compliance with all applicable laws and regulations.

LiveWire entered into an acquisition agreement with Botanical Intelligence, a company holding patented, advanced botanical-engraining technology. The Company plans to assemble a new development team to evaluate the technology, advance product development, and accelerate the commercialization of products arising from the acquisition.

Subsidiaries, parents, or affiliated companies.

ERF Ventures	Affiliate

B. Principal Products or Services.

LiveWire's product portfolio includes premium functional-wellness products and handcrafted cannabis-derived, hemp-derived THC, and CBD products developed for legally permitted medical and adult-use markets. The Company's products are manufactured and distributed through appropriately licensed entities in California and other U.S. jurisdictions where such activities are legally permitted.

The portfolio includes specialty products marketed under the Company's premium SOL VIDA™ Wellness brand.
LiveWire has entered into a Master Services and Licensing Agreement with ERF Ventures for business consulting and operational support. Services provided under the agreement include product design and development, marketing and sales support, regulatory compliance assistance, intellectual property management, operational oversight, and support in preparing and completing required license and permit applications. ERF Ventures also assists the Company in maintaining compliance with applicable licensing, permitting, and regulatory requirements governing its marketing, sales, and related business activities.

LiveWire does not knowingly manufacture, market, sell, or distribute products in violation of the U.S. Controlled Substances Act or other applicable federal, state, or local laws. The Company intends to conduct business—and acquire or maintain ownership interests—only in entities that operate in compliance with applicable laws and hold all licenses, permits, and regulatory approvals required for their activities

5) Issuer's Facilities

The Company leases space at the following locations:

LiveWire Ergogenics, Inc.
5165 Estrella Road
Paso Robles, CA 93446

The facility serves as the Company's administrative headquarters and provides the flexibility to expand operations and add personnel as business requirements evolve. Additional sales, marketing, market-awareness, and business-development services are provided by independent consultants located throughout the United States. These consultants are generally engaged on an as-needed basis, allowing the Company to access specialized expertise while maintaining a flexible and cost-efficient operating structure.

6) Officers, Directors, and Control Persons

We currently have two full-time contracted employees and several consultants based in California. Together, they oversee the Company's day-to-day operations in Anaheim and Paso Robles and support the management, engineering, and administration teams.

Name of Officer/Director and Control Person	**Affiliation with Company (e.g., Officer/Director/Owner of more than 5%)**	**Residential Address (City / State Only)**	**Number of shares owned**	**Share type/class**	**Ownership Percentage of Class Outstanding**
Bill Hodson	Board Member, Chief Executive Officer, Treasurer	Orange, CA	105,061,982	Comm	5.7%
Bill Hodson	Board Member, Chief Executive Officer, Treasurer	Orange, CA	75	Preferred C	100%
William Riley	President/Director	Las Vegas, NV	10,000,000	Comm	.0054%
Michael Corrigan	Director	Carlsbad, CA	5,000,000	Comm	.0027%

7) Legal/Disciplinary History

A. Please identify whether any of the persons or entities listed above have, in the past ten years, been the subject of:

1. An indictment or conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses).
   NO

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended, or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended, or otherwise limited such person's involvement in any business, securities, commodities, financial- or investment-related, insurance, or banking activities.

   NO

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

   YES, see Note C below.

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above, or

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any business or securities activities.

   YES, see Note C below

6. Been the subject of a U.S Postal Service false representation order, a temporary restraining order, or a preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

   NO

B. On May 3, 2018, American E Group LLC (AEG) filed a lawsuit against the Company in the United States District Court for the Southern District of New York. On March 10, 2022, an AAA arbitrator issued an award in favor of the Company and Mr. Hodson, finding that they had proven their counterclaims and that JSB had failed to prove its claim. The Arbitrator awarded the Company and Mr. Hodson a total of $352,493.02, including damages and arbitration costs, and ordered JSB to pay this sum by April 24, 2022. The Company has retained an attorney to explore all avenues for collecting the award.

C. On May 16, 2023, Livewire consented to an order by the SEC to pay a civil money penalty for Livewire's failure to comply with specific filing regulations of Regulation A, which it had filed on August 28, 2020. The SEC determined that the offering was not correctly registered with the Commission, but Livewire instead sought to rely on the limited exemption from regulation under Regulation A for the issuance of additional shares. The company will pay the Securities and Exchange Commission a civil penalty of $50,000 in three installments, with the first payment being due within 90 days of the date of the Order, the second within 180 days of the Order, the third within 270 days of the Order, and the fourth, plus all accrued interest, within 360 days of the Order. The company is currently negotiating a new payment schedule.

D. In July 2023, noteholder Osher Investments, LLC notified LiveWire that it had initiated legal proceedings seeking relief in connection with a loan transaction involving the Company. While the parties were engaged in settlement discussions, the noteholder continued the action and obtained a judgment against LiveWire. In a subsequent event (after the close of the 2nd quarter of 2026), the parties have since reached an initial settlement agreement, and a definitive agreement is in the final stages of preparation and execution. The proposed settlement remains subject to the execution of the final agreement and satisfaction of its applicable financial and other conditions. As of the date of this filing, a settlement has been agreed upon and is now final, the financial impact of which will be reflected in the next quarterly filing,

E. On October 19, 2023, we received a notice from Gusrae Kaplan Nussbaum PLLC (GKN) that it requested the entry of an order for a judgment against Livewire with the Court of New York for a remaining payment to GKN for representation in the case against American E Group LLC and JS Barkats, PLLC, in which Livewire obtained a judgment and an Arbitration award in favor of Livewire. Although Livewire has partially and periodically paid GKN a significant amount and considers the outstanding balance unreasonably high, GKN filed a request for an order with the New York court. Livewire instructed its attorneys to renegotiate the outstanding balance of the payment. The discussions are still ongoing, and GKN has not taken further action as of this date.

F. On May 15, 2024, we received a Complaint for breach of contract from the Estate of Larry Whitehead. Livewire had entered into a settlement agreement with Mr. Whitehead for repayment over time. After Mr. Whitehead's death, the Estate asserted non-fulfillment of the settlement agreement, sought repayment of the entire loan amount, and moved for entry of judgment. The Company is still trying to resolve this issue amicably.

8) Third-Party Providers

Please provide the name, address, telephone number, and email address of each of the following outside providers:

<u>Securities Counsel</u>

Name:	Michael Corrigan, Esq.
Firm:	Corrigan Law
Address 1:	10525 Vista Sorrento Pkwy, #200
Address 2:	San Diego, CA 92121
Phone:	619-535-1100
Email:	mike@corriganlaw.net

9) Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name:	Bill Hodson
Title:	CEO
Relationship with Issuer:	CEO

A. The following financial statements were prepared in accordance with the following:

☒ U.S. GAAP
☐ IFRS

B. The financial statements for this reporting period were prepared by:

Name:	Bill Hodson
Title:	CEO
Relationship with Issuer:	CEO

LIVEWIRE ERGOGENICS, INC.

CONSOLIDATED FINANCIAL STATEMENTS

FOR THE PERIODS ENDING JUNE 30, 2026, AND DECEMBER 31, 2025

LIVEWIRE ERGOGENICS, INC.
CONSOLIDATED BALANCE SHEET
FOR THE PERIOD ENDING JUNE 30, 2026, AND DECEMBER 31,2025
(UNAUDITED)

		June 30, 2026		December 31, 2025
ASSETS				
Current assets				
Cash	$	7,813	$	1,479
Accounts receivable	$	78,563		220,063
Due from related parties		-		-
Contract asset	$	22,000.00		22,000
Loan to related party		-		-
Total current assets	$	108,376		243,542
Fixed assets, net	$	339,324		164,696
Investment in Mojave Jane		-		-
Investment in Subsidiaries	$	1,790,297		1,853,881
Total other assets	$	2,129,621		2,018,577
Total Assets	$	2,237,997	$	2,262,119
LIABILITIES AND STOCKHOLDERS' DEFICT				
Current liabilities				
Accounts payable and accrued liabilities	$	80,928		86,158
Accrued Interest	$	599,474		640,041
Convertible notes-related party, net of unamortized discounts		-		-
Notes payable, net of unamortized discount	$	3,784,488		3,048,919
Notes payable - realted party		-		-
Total current liabilities	$	4,464,890		3,775,118
Total liabilities	$	4,464,890		3,775,118
Stockholders' Equity				
Preferred stock; $0.0001 par value; 9,899,925 shares authorized; 0 and 0 shares issued and outstanding of Marh 30, 2025 and December 31, 2024				
Preferred B stock; $0.0001 par value; 100,00 shares authorized; 45,120 shares issued and outstanding as of March 30, 2025 and December 31, 2024, respectively		-		-
Preferred C stock; $0.0001 par value; 75 shares authorized; March30, 2024 and December 31, 2024, respectively		-		-
Common stock; $0.0001 par value; 2,000,000,000 shares authorized; 1,903,979,092 and 1,903,979,092 shares issued and outstanding at March 30, 2025 and December 31, 2024, respectively	$	190,397		190,397
Additional paid-in capital	$	29,208,935		29,208,935
Stock payable	$	428,203		428,203
Accumulated Deficit	$	(32,054,428)		(31,340,534)
Total stockholder equity	$	(2,226,893)		(1,512,999)
Total liabilities and stockholders' equity	$	2,237,997	$	2,262,119

The accompanying notes are an integral part of these unaudited consolidated financial statements.

LIVEWIRE ERGOGENICS, INC.
CONSOLIDATED STATEMENT OF OPERATIONS
FOR THE PERIOD ENDING JUNE 30, 2026, AND JUNE 30, 2025
(UNAUDITED)

	For the three months Ended		For the six months Ended	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
Revenue	$ 13,700	$ -	$ 52,200	$ 53,000
Revenue - related party	-	-	-	153,535
Total revenue	$ 13,700	-	52,200	206,535
Cost of revenue	$ 5,995	-	11,770	-
Gross profit	$ 7,705	-	40,430	206,535
Operating expenses				
Professional fees	$ 12,000	15,000	27,000	71,291
General and administrative	$ 15,000	30,000	30,000	87,958
Depreciation and amortization	$ 6,319	6,319	12,638	12,638
Total operating expenses	$ 33,319	51,319	69,638	171,887
Other income (expense)				
Interest income - related party	-	-	-	183,810
Interest expense	$ (80,928)	(89,070)	(169,998)	(119,498)
Gain (loss) on extinguishment of debt	-	-	-	-
Gain (loss) on discontinued operations	$ (247,641)	(818,040)	(518,282)	
Total other income (expense)	$ (328,569)	(907,110)	(688,280)	64,312
Net income (loss)	$ (354,183)	$ (958,429)	$ (717,488)	$ 98,960
Income (loss) per common share - Basic	0.00	0.00	0.00	0.00
Income (loss) per common share - Diluted	0.00	0.00	0.00	0.00
Weighted average number of common shares outstanding - Basic	1,881,695,675	1,881,695,675	1,881,695,675	1,859,979,092
Weighted average number of common shares outstanding - Diluted	1,881,695,675	1,881,695,675	1,881,695,675	1,946,170,581

The accompanying notes are an integral part of these unaudited consolidated financial statements.

LIVEWIRE ERGOGENICS, INC.
CONSOLIDATED STATEMENT OF CASH FLOW
FOR THE PERIOD ENDING JUNE 30, 2026, AND JUNE 30, 2025
(UNAUDITED)

	For the Three Months Ended			
	June 30,2026		June 30,2025	
Cash flows from operating activities:				
Net income (loss)	$	(354,183)	$	(4,839,120.00)
Adjustments:				
Depreciation and amortization	$	6,319	$	6,319
Amortization of debt discount	$	-	$	-
Stock-based compensation	$	-	$	-
Gain (loss) from extinguishment of debt	$	-	$	-
Gain (loss) from discontinued operations	$	(247,641)	$	4,558,342
Changes in assets and liabilities, net of acquisition effects				
Accounts Receiveable	$	(78,563)	$	(530,063)
Notes receivable	$	-	$	-
Accounts payable	$	80,928	$	349,756
Accrued interest	$	599,474	$	453,501
Net cash provided by operating activities	$	6,334	$	(1,265)
Cash flows from investing activities:				
Investment in subsidiaries	$	-	$	-
Net cash used in investing activities	$	-	$	-
Cash flows from financing activities:				
Proceeds from notes payable	$	-	$	-
Payments on the notes payable	$	-	$	-
Proceeds from convertible debt	$	-	$	-
Payments on convertible debt	$	-	$	-
Proceeds from issuance of preferred stock	$	-	$	-
Net cash used in financing activities	$	-	$	-
Net decrease in cash and cash equivalents	$	6,334	$	(1,265)
Cash and cash equivalents at beginning of period	**$**	**1,479**	**$**	**8,400**
Cash and cash equivalents at end of period	**$**	**7,813**	**$**	**7,135**

The accompanying notes are an integral part of these unaudited consolidated financial statements.

LIVEWIRE ERGOGENICS, INC.
CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)
FOR THE PERIOD ENDING JUNE 30, 2026, AND JUNE 30, 2025 (UNAUDITED)

For the Years Ended December 30, 2024 and 2023

	Preferred Stock		Preferred Stock - B		Preferred Stock - C		Common Stock		Additional	Stock	Accumulated	Total Stockholders'
	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount	Paid-in Capital	Payable	Deficit	Equity (Deficit)
2024												
Balance, December 31, 2023	**-**	**$ -**	**32,820**	**$ 3.00**	**75**	**$ -**	**1,859,979,092**	**$ 185,998**	**$ 29,163,334**	**$ 428,203**	**$ (26,663,804)**	**$ 3,113,731**
Net income 3 months ended March 31, 2024	-	-	-	-	-	-	-	-	-	-	57,701	57,701
Balance, March 31, 2024	**-**	**$ -**	**32,820**	**$ 3**	**75**	**$ -**	**1,859,979,092**	**$ 185,998**	**$ 29,163,334**	**$ 428,203**	**$ (26,606,103)**	**$ 3,171,432**
Preferred shares issued for cash	-	-	12,300	1	-	-	-	-	49,999	-	-	50,000
Net income 3 months ended June 30, 2024	-	-	-	-	-	-	-	-	-	-	41,259	41,259
Balance, June 30, 2024	**-**	**$ -**	**45,120**	**$ 4**	**75**	**$ -**	**1,859,979,092**	**$ 185,998**	**$ 29,213,333**	**$ 428,203**	**$ (26,564,844)**	**$ 3,262,691**
Net loss 3 months ended September 30, 2024	-	-	-	(4)	-	-	-	-	-	-	(20,235)	(20,235)
Balance, September 30, 2024	**-**	**$ -**	**45,120**	**$ -**	**75**	**$ -**	**1,859,979,092**	**$ 185,998**	**$ 29,213,333**	**$ 428,203**	**$ (26,585,079)**	**$ 3,242,456**
Issued Common stock	-	-	-	-	-	-	44,000,000	4,399	(4,398)	-	-	-
Net loss 3 months ended December 31 2024	-	-	-	-	-	-	-	-	-	-	-	-
Balance, December 31, 2024	**-**	**$ -**	**45,120**	**$ -**	**75**	**$ -**	**1,903,979,092**	**$ 190,397**	**$ 29,208,935**	**$ 428,203**	**$ (26,585,079)**	**$ 3,242,456**
2025												
Net income 3 months ended March 31, 2025	-	-	-	-	-	-	-	-	-	-	(958,429)	(958,429)
Balance, March 31, 2025	**-**	**$ -**	**45,120**	**$ -**	**75**	**$ -**	**1,903,979,092**	**$ 190,397**	**$ 29,208,935**	**$ 428,203**	**$ (27,543,508)**	**$ 2,284,027**
Net income 3 months ended June 30, 2025	-	-	-	-	-	-	-	-	-	-	(958,429)	(958,429)
Balance June 30, 2025											**$ (28,501,937)**	**$ 1,325,598**
Net income 3 months ended September 30, 2025	-	-	-	-	-	-	-	-	-	-	(214,195)	(214,195)
Balance, September 30, 2025	**-**	**$ -**	**45,120**	**$ -**	**75**	**$ -**	**1,903,979,092**	**$ 190,397**	**$ 29,208,935**	**$ 428,203**	**$ (28,716,132)**	**$ 1,111,403**
Net income 3 months ended December 31, 2025	-	-	-	-	-	-	-	-	-	-	(22,498)	(22,498)
Balance, December 31, 2025	**-**	**$ -**	**45,120**	**$ -**	**75**	**$ -**	**1,903,979,092**	**$ 190,397**	**$ 29,208,935**	**$ 428,203**	**$ (31,340,534)**	**$ (1,512,999)**
2026												
Net income 3 months ended March 31, 2026	-	-	-	-	-	-	-	-	-	-	(359,711)	(359,711)
Balance, March 31, 2026	**-**	**$ -**	**45,120**	**$ -**	**75**	**$ -**	**1,903,979,092**	**$ 190,397**	**$ 29,208,935**	**$ 418,203**	**$ (31,700,245)**	**$ (1,872,710)**
Net Income 3 months ended June 30, 2026	-	$ -	-	$ -	-	$ -	-	-	-	-	-354183	$ (354,183)
Balance, June 30, 2026	**-**	**$ -**	**45,120**	**$ -**	**75**	**$ -**	**1,903,979,092**	**$ 190,397**	**$ 29,208,925**	**$ 418,203**	**$ (32,054,428)**	**$ (2,226,893)**

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Notes to Financial Statements

Management’s Discussion and Analysis of Financial Condition and Results of Operations

LiveWire Ergogenics, Inc. (“LiveWire” or the “Company”) develops, licenses, and markets distinctive, high-quality functional wellness, cannabinoid, hemp-derived THC, and CBD products and accessories intended for legally permitted medical and adult recreational markets. The Company’s portfolio includes specialty products offered under its premium SOL VIDA™ Wellness brand. The Company’s products are intended to be manufactured and distributed through appropriately licensed entities in California and other permitted U.S. markets, subject to applicable federal, state, and local laws and regulations.

Transition from Cultivation Operations
During the first quarter of 2025, at LiveWire’s request, its subsidiary, Estrella Ranch Partners, LLC (“ERP”), ceased cultivation operations at Estrella Ranch. This decision was made to eliminate the substantial operating expenses and regulatory burdens associated with maintaining the property and conducting large-scale cannabis cultivation. These expenses included mortgage payments, property maintenance, utilities, permitting, regulatory compliance, and other operating costs, a significant portion of which had been funded through loans from LiveWire to ERP.

ERP subsequently transferred the Grant Deed for Estrella Ranch back to the original owners, terminating ERP’s and LiveWire’s continuing operational and financial obligations associated with ownership of the property. Management expects that eliminating these substantial fixed costs and using lower-cost, high-quality raw materials obtained from qualified third-party suppliers for manufacturing the Company’s product line will materially improve the Company’s operating structure and financial position.

Estrella Ranch Property
LiveWire previously reached a verbal understanding with the current owner regarding a potential continuing equity interest in Estrella Ranch. The property is now reportedly in the process of being acquired by another prospective owner. To the Company’s knowledge, the transaction has not yet been completed, and the prior verbal understanding has not been formalized with the prospective new owner. Accordingly, no definitive agreement has been executed, and there can be no assurance that LiveWire will obtain or retain any equity interest in the property following a transfer of ownership.

Regardless of whether an agreement concerning the property is ultimately reached, LiveWire intends to continue accelerating the development and commercialization of products for the functional wellness market. The Company remains committed to maintaining a lean operating structure, controlling overhead, and sharing appropriate resources with its strategic partners, manufacturers, affiliates, and subsidiaries. This structure is intended to eliminate the need for the Company to own and operate a large cultivation or processing facility.

Revised Business Model and Product Strategy
The Company is placing greater emphasis on the development, licensing, marketing, and sale of general functional wellness products, complemented by specialty cannabinoid, hemp-derived THC, and CBD products. This portfolio includes products offered under the Company’s premium SOL VIDA™ Wellness brand.

These products are being developed for distribution within the broader U.S. wellness market. They are expected to command higher selling prices and generate stronger profit margins than the Company’s former cultivation operations and wholesale bulk-flower sales. Management believes the revised business model may also provide more stable and predictable year-round revenue while substantially reducing the Company’s fixed operating costs and exposure to commodity price fluctuation.

The remaining inventory from Estrella River Farms’ final harvest, together with raw materials sourced from qualified third-party suppliers, is intended to support the Company’s transition to a product-focused business model. Subject to applicable legal and regulatory requirements, the existing inventory is expected to be processed into high-quality cannabinoid oil for use in selected SOL VIDA™ Wellness products and other specialty formulations.

Manufacturing and Strategic Relationships
The Company has established relationships with carefully selected wellness and cannabis-industry professionals, product developers, raw-material suppliers, processors, manufacturers, and distributors. These relationships are intended to support the design, development, manufacture, marketing, distribution, and sale of the Company’s products in California and other legally permitted U.S. markets.

LiveWire intends to engage only qualified and appropriately licensed processors and manufacturers to convert its existing inventory and qualified third-party raw materials into finished products for the SOL VIDA™ Wellness product line and other specialty products.

The Company has also entered into a Master Service and Licensing Agreement with ERF Ventures for general business consulting and support services. These services include product design, marketing and sales support, regulatory compliance, intellectual-property management, operational supervision, and assistance with the preparation and completion of required permit applications. ERF Ventures also assists the Company with maintaining ongoing compliance with applicable permitting conditions related to its marketing, sales, and general business activities.

Regulatory Compliance
LiveWire intends to conduct business and maintain ownership interests only in entities that comply with applicable federal, state, and local laws and regulations and possess the licenses, permits, and regulatory approvals required for their respective operations.
The Company does not knowingly manufacture, market, sell, or distribute any product in violation of the United States Controlled Substances Act or other applicable laws. All manufacturing, marketing, sales, and distribution activities are intended to be conducted through appropriately licensed entities and in accordance with the requirements of each applicable jurisdiction.

Critical Accounting Policies

The preparation of our consolidated financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and judgments that affect our reported assets, liabilities, revenues, and expenses, and the disclosure of contingent assets and liabilities. We base our estimates and judgments on historical experience and on various other assumptions we believe to be reasonable under the circumstances. Future events, however, may differ markedly from our current expectations, assumptions, or projections. While there are several significant accounting policies affecting our consolidated financial statements, we believe the following critical accounting policies involve the most complex, difficult and subjective estimates and judgments.

Accounts Receivable – We evaluate our trade accounts receivable collectability based on several factors. In circumstances where we become aware of a specific customer's inability to meet its financial obligations to us, a specific reserve for bad debts is estimated and recorded, which reduces the recognized receivable to the estimated amount we believe will ultimately be collected. In addition to specific customer identification of potential bad debts, bad debt charges are recorded based on our recent loss history and an overall assessment of past-due trade accounts receivable outstanding.

Inventories – Inventories are stated at the lower of cost to purchase and manufacture the inventory or the current estimated market value of the inventory. We regularly review our inventory quantities on hand and record a provision for excess and obsolete inventory based primarily on our estimated forecast of product demand, production availability, and our ability to sell the products concerned. Demand for our products can fluctuate significantly. Factors that could affect the demand for our products include unanticipated changes in consumer preferences, general market, and economic conditions, or other factors that may result in cancellations of advance orders or reductions in the rate of reorders placed by customers, and continued weakening of economic conditions. Additionally, management's estimates of future product demand may be inaccurate, which could result in an understated or overstated provision required for excess and obsolete inventory.

Long-Lived Assets – Management regularly reviews property and equipment and other long-lived assets, including certain definite-lived identifiable intangible assets for possible impairment. This review occurs annually or more frequently if events or changes in circumstances indicate that the asset's carrying amount may not be recoverable. If there is an indication of impairment of property and equipment or amortizable intangible assets, then management prepares an estimate of future cash flows (undiscounted and without interest charges) expected to result from using the asset and its eventual disposition. If this cash is less than the asset's carrying amount, an impairment loss is recognized to write down the asset to its estimated fair value. The fair value is estimated at the present value of the future cash flows discounted at a rate commensurate with management's estimates of the business risks.

Revenue Recognition – We recognize revenue when persuasive evidence of an arrangement exists, and the delivery has occurred, the sales price is fixed or determinable, and collectability is reasonably assured. Generally, ownership of and The title of our products will be passed on to customers upon delivery. Net sales have been determined after deducting promotional and other allowances per ASC 605-50. Amounts received according to new and amended distribution agreements entered into with certain distributors, relating to the costs associated with terminating prior distributors, are accounted for as revenue ratably over the expected life of the respective distribution agreement, generally 20 years. Management believes that adequate provision has been made for cash discounts, returns, and spoilage based on our historical experience.

Cost of Sales – Cost of sales consists of the costs of products distributed, inbound freight charges, as well as certain internal costs. transfer to warehouse expenses incurred before delivery. Variable product costs account for the most significant portion of the cost of sales.

Operating Expenses – Operating expenses include selling expenses such as distribution expenses to transport products to customers, warehousing expenses, advertising, commissions, and other marketing expenses. Operating expenses also include payroll costs, travel costs, professional service fees, legal fees, entertainment, insurance, postage, depreciation, and other general and administrative expenses.

Income Taxes – We utilize the liability method of accounting for income taxes as outlined in ASC 740. Under the liability method, deferred taxes are determined based on the temporary differences between the financial statement and the tax basis of assets and liabilities using tax rates expected to be in effect during the years the basis differences reverse. A valuation allowance is recorded when it is more likely that some deferred tax assets will not be realized. In determining the need for valuation allowances, we consider projected future taxable income and the availability of tax planning strategies. If in the future we determine that we would not be able to realize our recorded deferred tax assets, an increase in the valuation of the allowance would be recorded, decreasing earnings in the period in which such a determination is made.

We assess our income tax positions and record tax benefits for all years subject to examination based upon our evaluation of the facts, circumstances, and information available at the reporting date. For those tax positions where there is a greater than 50% likelihood that a tax benefit will be sustained, we have recorded the most significant amount of tax benefit that may potentially be realized upon ultimate settlement with a taxing authority that knows all relevant information. For those income tax positions where there is less than a 50% likelihood that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements.

Derivative Liabilities - The Company assessed the classification of any derivative financial instruments as of June 30, 2024, which consists of Convertible instruments and rights to shares of the Company's common stock, and determined that such Derivatives meet the criteria for liability classification under ASC 815. ASC 815 generally provides three criteria require companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles, with changes in fair value reported in earnings as they occur, and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirements of ASC 815. ASC 815 also provides an exception to this rule when the host instrument is deemed to be conventional, as described.

Fair Value of Financial Instruments - The Company has adopted FASB ASC 820 Fair Value Measurements and Disclosures. or ASC 820, for assets and liabilities measured at fair value regularly. ASC 820 establishes a standard definition for fair value be applied to existing accepted accounting principles that require using fair value measurements to develop a framework for measuring fair value, and expanding disclosure about such fair value measurements. The adoption of ASC 820 did not impact the Company's financial position or operating results but did expand certain disclosures.

ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize unobservable inputs. These inputs are prioritized below:

Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data
Level 3: Unobservable inputs for which there is little to no market data, which require the use of the reporting entity's own assumptions.

The Company did not have any Level 2 or Level 3 assets or liabilities as of June 30, 2024, except for its convertible notes payable and derivative liability. The carrying amounts of these liabilities on June 30, 2024, approximate their respective fair value based on the Company's incremental borrowing rate.

Cash is considered to be highly liquid and easily tradable as of June 30, 2024, and therefore classified as Level 1 within our fair value hierarchy.

FASB ASC 825-10-25 Fair Value Option, or ASC 825-10-25, was effective on January 1, 2008. ASC 825-10-25 expands opportunities to use fair value measurements in financial reporting and permits entities to choose to measure many financial instruments and certain other items at fair value. The Company did not elect the fair value options for any of its qualifying financial instruments.

Convertible Instruments - The Company evaluates and accounts for conversion options embedded in its convertible instruments following professional standards for "Accounting for Derivative Instruments and Hedging Activities. Professional standards generally provide three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic charact eristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes the fair value reported in earnings as they occur, and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Professional standards also provide an exception to this rule when the host instrument is deemed conventional, defined as a "Conventional Convertible Debt Instrument."

The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) following professional standards when "Accounting for Convertible Securities with Beneficial Conversion Features," as those professional standards pertain to "Certain Convertible Instruments. Accordingly, The company records, when necessary, discounts to convertible notes for the intrinsic value of the conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the Note. Debt discounts under these arrangements are amortized over the term of the related debt to their earliest date of redemption. The Company also records when necessary deemed dividends for the intrinsic value of conversion options embedded in preferred shares, based on the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the Note.ASC 81540 provides that, among other things, generally, if an event is not within the entity's control, it could or requires net cash settlement. The contract shall be classified as an asset or a liability.

Results of Operation

The Company has now reached the final phase of the transition to our revised business model. Some of the changes and their financial impact were already reflected in our Q3 report. This annual report reflects all adjustments, including uncollectible Receivables, aged-out Payables, and eliminated Notes Payable, based on our in-depth impact analysis and subsequent balance sheet adjustments.

Comparison of the Results of Operations for the Quarter ending June 31, 2026, and 2025

During the quarter ending June 30, 2026, we generated a net loss of $354,183 compared to a net loss of $958,429 during the fiscal year ending June 30, 2025, a decrease of $604,246.

During the quarter ending June 30, 2026, and June 30, 2025, sales amounted to $13,700 and $0.00, respectively, an increase of $13,700.

Loss from Operations. For the quarter ended June 30, 2026, the Company reported a net loss of $354,183, compared with a net loss of $958,429 for the quarter ended June 30, 202, an improvement of $604,246, or approximately 63%. The reduction in net loss was primarily attributable to the elimination of significant operating expenses associated with the Company's transition to its revised business model.

General and administrative expenses decreased to $15,000 from $30,000, a reduction of $15,000, or 50%. Professional fees decreased to $12,000 from $15,000 for the comparable 2025 quarter, a reduction of $3,000, or 20%.

As of June 30, 2026, the Company had not issued any additional shares, and 1,903,979,092 shares of common stock were issued and outstanding. The Company's securities are currently quoted on the OTCID market**.**

Current Assets and Liabilities. As of June 30, 2026, assets decreased to $2,129,621, down $132,498 from December 31, 2024. Our liabilities exceeded our assets by $2,226,893.

Costs and Expenses

General and Administrative. During the quarter ending June 30, 2026, general and administrative expenses amounted to $15,000, a decrease of $15,000 from $30,000 during the same period in 2025. The decrease is due to reduced use of consultants and advisors during the transition period.

Professional Fees. For the quarter ending June 30, 2026, Professional Fees were $12,000, a reduction of $3,000 compared to 2025, due to lower legal and general consulting fees.

Interest expense. For the quarter ending June 30, 2026, interest expense was $80.928, compared to 89.070 during the quarter ending June 30, 2025, for continuing interest in short-term loan instruments.

Gain on change in fair value of the derivative liability. Our accompanying consolidated financial statements describe how we issue convertible notes with certain conversion features and specific reset provisions. All of which we are required to bifurcate from the host financial instrument and mark to market each reporting period. We recorded the initial fair value of the reset provision as a liability with an offset to equity or debt discount, and subsequently marked to market the reset provision liability at each reporting cycle. For the quarter ending June 30, 2026, we recorded a derivative liability of $0 compared to $0 for the quarter ending June 30, 2025. We recorded interest income of $0.00 in 2026, compared to $0.00 in 2025.

Going Concern. The Company's consolidated financial statements have been prepared in accordance with U.S. GAAP applicable to a going concern, which contemplates the realization of assets and settlement of liabilities in the ordinary course of business. As of June 30, 2026, the Company had an accumulated deficit of $32,054,428, compared with $31,340,534 as of June 30, 2025, representing an increase of $713,894. As of June 30, 2026, the Company's liabilities exceeded its assets by $2,226,893.

The Company's ability to continue as a going concern, establish reliable revenue sources, and achieve profitable operations depends, among other factors, on obtaining additional capital. Management's plans include increasing product sales, raising additional capital, and issuing shares of the Company's common stock. However, there can be no assurance that the Company will successfully implement these plans, obtain sufficient financing, or achieve profitable operations.

The Company's ability to continue as a going concern is dependent upon its successful execution of these plans, its ability to secure additional financing, and its eventual achievement of profitable operations. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability or classification of recorded assets or the amounts and classification of liabilities that might be necessary if the Company is unable to continue as a going concern.

Principal Executive Officer:

I, Bill Hodson, certify that:

1. I have reviewed this Quarterly Disclosure Statement for Livewire Ergogenics, Inc.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances under which such statements were made, not misleading concerning the period covered by this disclosure statement; and

3. To the best of my knowledge, the financial statements and other financial information included or incorporated by reference in this disclosure statement present in all material aspects the issuer's financial condition, results of operations, and cash flows as of and for the periods presented in this disclosure statement.

Dated: August 12, 2026

By:/s/ Bill J. Hodson
Chief Executive Officer

Principal Financial Officer:

I, Bill Hodson, certify that:

1. I have reviewed this Disclosure Statement for Livewire Ergogenics, Inc.

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations, and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Dated: August 12, 2026

By:/s/ Bill J. Hodson
Principal Financial Officer